🔗 Share this article

Given that America continues making historic changes to its vaccination schedules, an unexpected name has surfaced unexpectedly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 vaccinations during the global health crisis and has zeroed in on possible fatalities after Covid immunization in her recent tenure at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Health officials planned to announce sweeping changes to the childhood immunization program earlier this month, synchronizing the US with Denmark’s vaccine program, it is understood – a substantial departure that would put the US at odds with much of the world with no evidence for improved outcomes. The planned update has been delayed until the next year.

Rather than Vinay Prasad, Dr. Høeg is set to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

Consolidating Power at the Agency

This interim role might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon dismantling long-standing immunizations at the FDA.

Høeg has often pushed for discontinuing certain childhood shot schedules in the US so as to align more like Denmark's approach, a country with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date comments, she has continued to focus on immunizations – usually the purview of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Dr. Høeg has little discernible track record in pharmaceutical research, approval processes or management, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Former directors of CBER would “be deeply familiar with legal statutes and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the type of experience that former directors who ran CBER have had.”

CDER has an enormous range of responsibilities at the agency, the former commissioner stated.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes a multitude of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and all of those need to be managed,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major leadership element to the position, which oversees over 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Contentious Initiatives

In response to inquiries about Høeg’s credentials and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a representative said that the “concerns stem from incorrect assumptions”.

“This background aligns with the functions of her job,” the spokesperson stated, citing the time Høeg spent counseling the agency head on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s new priority voucher program, a disputed expedited medication authorization process that allegedly concerned her preceding directors. “How are these drugs being chosen for this fast-track system? Who is making the calls?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Public History on Vaccines

With vaccines, Høeg has a clearer, if troubling, track record, some experts observe. She authored a study using non-validated crowd-sourced reports to assess the frequency of heart inflammation following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who reportedly have changed statistics to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership encompassed changing guidelines for recently developed shots and ending “non-essential” immunizations, she remarked following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of barring young men from receiving Covid vaccinations.

“She’s an all-around dogmatist who begins with her conclusions and works backwards to retrofit the science in a very misleading, untruthful way,” Howard said.

Taking Control and a “Revenge Tour”

Høeg joined fellow skeptics, {like|